Handelsavisen
prelaunch
Companies Healthcare AMBL.BO
AM
AMBL.BO BSE (India) Pharmaceuticals

Ambl.Bo

$32,34
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-0,1 %
ROE
3,5 %
Net margin
2,5 %
Debt / equity
0,36
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Ambika Medicare Limited (AMBL.BO) operates in the Pharmaceuticals industry, manufacturing and distributing generic and branded pharmaceutical products in India.

Business. Ambika Medicare Limited (AMBL.BO) operates in the Pharmaceuticals industry, manufacturing and distributing generic and branded pharmaceutical products in India.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
3,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning AMBL.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to AMBL.BO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Ambika Medicare Limited (AMBL.BO) operates in the Pharmaceuticals industry, manufacturing and distributing generic and branded pharmaceutical products in India.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure shows a debt-to-equity ratio of 0.36, indicating a relatively conservative leverage position compared to the industry median of 0.50. However, liquidity remains a concern, with a current ratio of 0.98 and negative net cash after subtracting total debt. Free cash flow of INR 62.2 million is positive but insufficient to cover operating cash outflows of INR 176.2 million.

    Profitability metrics are mixed. Return on equity (ROE) of 3.52% is below the industry median of 5.0%, while return on assets (ROA) of 1.83% is also below the median of 3.0%. Operating income is negative at INR 1.55 million, contrasting with a net income of INR 49.3 million, suggesting non-operating income or gains may be offsetting operational losses.

    Geographic and segment exposure is not disclosed in the available data, but the company's revenue of INR 1.96 billion is concentrated in the Indian market. No material revenue diversification across regions or product lines is evident from the financial snapshot.

    Growth trajectory is uncertain. Historical revenue data is not provided, but the outlook for the current fiscal year shows no clear direction. The company's operating cash flow is negative, and capital expenditures of INR 27.2 million are modest relative to asset size. No significant revenue growth drivers are identified in the available data.

    Risk factors include medium liquidity risk due to a current ratio below 1 and negative net cash after debt. Dilution risk is low, with no difference between basic and diluted shares outstanding. However, the company's operating losses and negative cash flow from operations suggest potential future financing needs that could lead to dilution.

    Recent events include a 10-K filing that highlights operational challenges and a transcript from a recent earnings call discussing cost management strategies. No major regulatory or geopolitical events are disclosed in the available data.

    Key takeaways
    • AMBL.BO has a conservative debt-to-equity ratio but faces liquidity challenges with a current ratio below 1.
    • ROE and ROA are below industry medians, indicating weaker profitability relative to peers.
    • Operating income is negative, but net income is positive, suggesting reliance on non-operating income.
    • Growth trajectory is unclear, with no significant revenue expansion or capital investment trends.
    • Liquidity risk is medium, and dilution risk is low in the near term.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $32,34
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.40B
    Net cash
    -$487.9M
    Current ratio
    1.0
    Debt / equity
    0.4
    ROA
    1.8%
    ROE
    3.5%
    Cash conversion
    -357.0%
    CapEx / revenue
    -1.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-0,1 %Below median
    Net Margin2,5 %Below median
    ROE3,5 %Above median
    Capex / Rev-1,4 %Above P75
    D/E0,36Below median
    Cash Conv-3,57Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • AMBL.BO Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    AMBL.BOCanonical
    BSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage